PrEParing to End the Epidemic
Optimizing HIV Prevention in Primary Care
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.
Emtricitabine/tenofovir alafenamide.
HIV.gov. Drug database.
Emtricitabine/tenofovir disoproxil fumarate.
HIV.gov. Drug database.
Cabotegravir.
HIV.gov. Drug database.
Being PrEPared—preexposure prophylaxis and HIV disparities.
Goldstein RH, et al. N Engl J Med. 2018;379(14):1293-1295.
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant RM, et al. N Engl J Med. 2010;363(27):2587-2599.
Lifetime risk of a diagnosis of HIV infection in the United States.
Hess KL, et al. Ann Epidemiol. 2017;27(4):238-243.
Cabotegravir for HIV prevention in cisgender men and transgender women.
Landovitz RJ, et al. N Engl J Med. 2021;385(7):595-608.
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH, et al. Lancet. 2020;396(10246):239-254.
Clinical Commissioning Policy. Reimbursement for the use of generic drugs for pre exposure prophylaxis (PrEP) for the prevention of HIV.
National Health Service. 2020.
How to incorporate HIV PrEP into your practice.
Stewart J, Stekler JD. J Fam Pract. 2019;68(5):254-261.
Patient and Provider assistance: PleasePrEPMe.org
Information about PrEP, nPEP, insurance and insurance rights, finding a PrEP/nPEP provider, and a list of PrEP resources by state
Provider assistance: AETC; AIDS Education & Training Center Program: National Coordinating Resource Center
Supports national HIV priorities by providing training, consultation, and resources
Ready, Set, PrEP! provides free PrEP HIV-prevention medication
Clinic visits and lab tests vary depending on income
If PrEP medication is a good option for your clients, they can choose the application process that is most convenient
By phone: 855-447-8410
Patient assistance (without insurance)
The PrEP patient assistance program will provide medication at no cost for those who meet income guidelines
Uninsured 24/7 support online, by phone during business hours and fax enrollment
Copay assistance (for patients with nongovernment insurance)
Phone number: 1-877-505-6986
Copay assistance/out-of-pocket costs
ViiV Connect
Patient Poster
Clinical Practice Guidelines
Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update). A clinical practice guideline.
US Public Health Service. Centers for Disease Control and Prevention; 2021.
Sexually transmitted infections treatment guidelines. 2021.
Centers for Disease Control and Prevention. Last reviewed July 2021.
2018 quick reference guide: recommended laboratory HIV testing algorithm for serum or plasma specimens.
CDC Stacks. Centers for Disease Control and Prevention; last updated January 2018.
Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016.
CDC Stacks. Centers for Disease Control and Prevention; last updated May 2018.
HIV pre-exposure prophylaxis in the EU/EEA and the UK: implementation, standards and monitoring: technical guidance.
European Centre for Disease Prevention and Control (ECDC). 2021.
The Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health.
Makadon H, et al, American College of Physicians (ACP), eds. 2nd ed. Boston, MA: Fenway Health; 2015.
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society—USA Panel.
Saag MS, et al. JAMA. 2020;324(16):1651-1669.
Professional Organizations & Resources
American Academy of HIV Medicine.
Basic statistics.
Centers for Disease Control and Prevention; updated April 2022.
National Clinician Consultation Center.
University of California, San Francisco; 2020.
HIV drug interactions.
University of Liverpool (website); updated April 2022.
PrEParing to End the Epidemic
Optimizing HIV Prevention in Primary Care
| Faculty: | Shauna Applin, A-NP, AAHIVs |
| Release: | 12/16/2022 |
| Expiration: | 12/16/2023 |
